SCHEMBL5319953

SCHEMBL5319953

CCC(CCC(N)C(=O)O)C(N)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 6/20 0.55
SLC1A1 P43005 6/20 0.55
SLC1A3 P43003 5/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
GCLC P48506 2/20 0.53
ALOX15 P16050 1/20 0.48
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
KMT2A Q03164 1/20 0.48
GRIK1 P39086 3/20 0.47
GRIK2 Q13002 3/20 0.47
GRM8 O00222 1/20 0.45
GRM6 O15303 1/20 0.45
GRIN2D O15399 1/20 0.45
GRIN3B O60391 1/20 0.45
GSR P00390 1/20 0.45
CYP1A2 P05177 1/20 0.45
GRM5 P41594 1/20 0.45
GRIA1 P42261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5320933 0.86 SLC1A2 (0.60) SLC1A2SLC1A1SLC1A3CA1CA2
SCHEMBL5324268 0.81 SLC1A2 (0.76) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL27467303 0.81 SLC1A2 (0.76) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL15778941 0.77 KMT2A (0.61) SLC1A2SLC1A1SLC1A3ALOX15BLM
SCHEMBL15778940 0.77 KMT2A (0.61) SLC1A2SLC1A1SLC1A3ALOX15BLM
SCHEMBL15778942 0.77 KMT2A (0.61) SLC1A2SLC1A1SLC1A3ALOX15BLM
SCHEMBL8068164 0.76 GSR (0.68) SLC1A2SLC1A1SLC1A3ALOX15BLM
SCHEMBL602426 0.76 GSR (0.68) SLC1A2SLC1A1SLC1A3ALOX15BLM
SCHEMBL25342795 0.76 GCLC (0.53) SLC1A2SLC1A1SLC1A3GCLCALOX15
SCHEMBL14571349 0.76 CA2 (0.68) SLC1A2SLC1A1SLC1A3CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 SLC1A2 4787/4885SLC1A1 4654/4885SLC1A3 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.